

This is a repository copy of *A tale of two bioconjugations : pH controlled divergent reactivity of protein α -oxo aldehydes in competing α -oxo-Mannich and catalyst-free aldol ligations.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/179553/>

Version: Accepted Version

Article:

Keenan, Tessa, Spears, Richard J, Akkad, Saeed orcid.org/0000-0002-7271-0496 et al. (9 more authors) (2021) A tale of two bioconjugations : pH controlled divergent reactivity of protein α -oxo aldehydes in competing α -oxo-Mannich and catalyst-free aldol ligations. ACS Chemical Biology. pp. 2387-2400. ISSN 1554-8937

<https://doi.org/10.1021/acscchembio.1c00531>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

1 **A tale of two bioconjugations: pH controlled divergent reactivity of protein α -oxo aldehydes**
2 **in competing α -oxo-Mannich and catalyst-free aldol ligations**

3 Tessa Keenan¹, Richard J. Spears¹, Saeed Akkad¹, Clare S. Mahon², Natasha E. Hatton¹, Julia Walton¹,
4 Amanda Noble¹, Nicholas D. Yates¹, Christoph G. Baumann³, Alison Parkin¹, Nathalie Signoret⁴,
5 Martin A. Fascione^{1*}

6

7 ¹Department of Chemistry, University of York, York, UK, YO10 5DD; ²Department of Chemistry,
8 Durham University, UK, DH1 3LE Durham; ³Department of Biology, University of York, York, UK, YO10
9 5DD; ⁴Hull York Medical School, University of York, York, UK, YO10 5DD

10 *Corresponding author, martin.fascione@york.ac.uk

11 **ABSTRACT**

12 Site-selective chemical methods for protein bioconjugation have revolutionised the fields of cell and
13 chemical biology through the development of novel protein/enzyme probes bearing fluorescent,
14 spectroscopic or even toxic cargos. Herein we report two new methods for the bioconjugation of α -
15 oxo aldehyde handles within proteins using small molecule aniline and/or phenol probes. The ‘ α -oxo-
16 Mannich’ and ‘catalyst-free aldol’ ligations both compete for the electrophilic α -oxo aldehyde which
17 displays pH divergent reactivity proceeding through the “Mannich” pathway at acidic pH to afford
18 bifunctionalised bioconjugates, and the “catalyst-free aldol” pathway at neutral pH to afford
19 monofunctionalised bioconjugates. We explore the substrate scope and utility of both these
20 bioconjugations in the construction of neoglycoproteins, in the process formulating a mechanistic
21 rationale for how both pathways intersect with each other at different reaction pH.

22

23 **INTRODUCTION**

24 Methods to site-selectively adorn biomolecules with small molecules is of major interest within the
25 field of chemical biology as modification with functional moieties can vastly enhance their properties.¹⁻
26 ² For example, bioconjugation of compounds such as polyethyleneglycol can improve the half-life of
27 protein probes and therapeutics,³⁻⁴ whilst ligation of fluorescent/spectroscopic probes has been
28 utilised for *in vivo* imaging and tracking of proteins, carbohydrates and DNA.⁵⁻⁹ Furthermore the ability
29 to chemically generate proteins bearing ‘mimics’ of post-translational modifications such as
30 glycosylation,¹⁰⁻¹⁵ has armed biologists with tools to study modified proteins that may be otherwise
31 challenging to obtain using standard recombinant expression techniques.

32 However, the development of new methods in this field has relied heavily on the modification
33 of a small number of amino acid residues which are surface exposed or in low natural abundance,¹⁶⁻²⁶
34 or well-studied unnatural azide, alkyne or olefin handles.²⁷⁻³⁰ Alternatively, non-proteinogenic
35 aldehyde chemical handles which have also been incorporated into biomolecule scaffolds³¹ are
36 relatively underexplored in comparison. In particular, α -oxo aldehydes,³² which can now be routinely

37 incorporated site-selectively at both *N*-terminal and internal positions within proteins³³⁻³⁵ and offer
 38 great potential for the development of novel bioconjugations due to their uniquely electrophilic
 39 nature. Although recent studies have shown these α -oxo aldehydes are reactive in C-C ligations,³⁶⁻³⁷
 40 much of the work in this field has been focussed on the synthesis of heteroatom linked thiazolidine,³⁸
 41 oxime and hydrazone bioconjugates from aldehyde precursors.³⁹⁻⁴¹ These transformations have
 42 principally employed anilines as organocatalysts leading to large increases in reaction rates at neutral
 43 pH or below.⁴²⁻⁴⁶ This acceleration is facilitated by the ability of the aniline to rapidly react with the
 44 aldehyde under physiological conditions and form a more reactive Schiff base, which is then attacked
 45 by a reactive α -effect nucleophile resulting in the expulsion of the aniline catalyst in an example of
 46 *trans*-imination. Prior to this widespread application of anilines as organocatalysts in bioconjugations
 47 however, pioneering studies by Francis and co-workers demonstrated anilines could also be
 48 incorporated into protein bioconjugates by exploiting exposed tyrosine residues as nucleophiles to
 49 trap small molecule Schiff bases in a “three-component Mannich” reaction.⁴⁷ Although powerful in its
 50 ability to generate useful multicomponent products this Mannich transformation has been
 51 underutilised since its discovery and is potentially limited by lack of site-selectivity due to the
 52 abundance of exposed phenolic tyrosine residues within proteins. To overcome this issue, in this study
 53 we explored whether proteins bearing site-selectively installed α -oxo aldehyde handles could act as
 54 electrophilic scaffolds for novel α -oxo-Mannich bioconjugations wherein the aniline and the phenol
 55 components are both small molecules. Herein, not only do we describe the realisation of this approach
 56 in the development of multicomponent α -oxo-Mannich ligations on proteins, but also a divergence in
 57 the reactivity of α -oxo aldehydes in the presence of anilines and phenols at different pH (Fig. 1).
 58 Notably at acidic pH α -oxo aldehydes react as anticipated to through a “Mannich” pathway to afford
 59 bifunctionalised bioconjugates, but at neutral pH we demonstrate phenols react directly with α -oxo




Fig. 1 pH dependant α -oxo-Mannich and catalyst-free aldol bioconjugation of protein α -oxo aldehydes using anilines and phenols.

60 aldehydes in a rapid “catalyst-free aldol” pathway to afford monofunctionalised bioconjugates. We
61 use model peptides and proteins to explore the substrate scope and utility of both these
62 bioconjugations and in the process formulate a mechanistic rationale for how both pathways compete
63 and intersect with each other depending on reaction pH.

64

65 RESULTS

66 Peptide feasibility studies

67 We investigated the feasibility of the proposed α -oxo-Mannich bioconjugation using a model peptide
68 α -oxo-aldehyde-VARLG **1** that lacked tyrosine residues. Reactions were assembled with α -oxo-
69 aldehyde-VARLG **1**, commercially available aniline **2** and substituted 4-methoxy phenol **3** or 3,5-
70 dimethoxy phenol **4** in phosphate buffer (PB) at pH 6.5 (Fig. 2a) to replicate conditions previously
71 reported for Mannich reactions on tyrosine residues in proteins.⁴⁸⁻⁴⁹ Relative conversion to the
72 anticipated α -oxo-Mannich products **5** and **6** were assessed by LC-MS analysis. Pleasingly the
73 anticipated α -oxo-Mannich products were observed in both reactions and these were validated by
74 MS/MS analysis (Fig. S5-S6 and S8). However, only 12% relative conversion to α -oxo-Mannich product
75 **5** was observed in the reaction with 4-methoxy phenol **3** with a significant quantity of starting material
76 **1** remaining suggesting that the conditions required significant optimisation. Additionally, in the
77 reaction with the more electron rich 3,5-dimethoxy phenol **4**, a significant amount of an unanticipated
78 species **7** at 725.43 *m/z* was observed alongside α -oxo-Mannich product **6**. Interestingly, the *m/z* value
79 of the unanticipated species **7** corresponds to the mass of α -oxo-aldehyde-VARLG **1** + the mass of
80 phenol **4** (+1 Da for [M+H]⁺). Subsequent MS/MS analysis of species **7** yielded a fragmentation pattern
81 similar to that described for aldol-modified peptides,³⁷ with the modification identified at the *N*-
82 terminus and a highly intense peak of species -18 Da, which upon fragmentation yielded *x/y/z*
83 fragments corresponding to the “VARLG” peptide (Fig. 2b, Fig. S9-S10). As modifications of small
84 molecule aldehydes⁵⁰ and other protein electrophiles⁵¹ have previously been reported under aqueous
85 conditions using phenol reagents proposed to act as enolate equivalents, we hypothesised that phenol
86 **4** may be participating as a preformed enol equivalent in a direct aldol-type conjugation with α -oxo-
87 aldehyde VARLG **1**. To validate this hypothesis, α -oxo-aldehyde VARLG **1** was incubated with different
88 concentrations of phenol **4** in PB at pH 6.5 for 24 h in the absence of aniline and 95% relative
89 conversion to the anticipated aldol product **7** was observed using only 1 molar equiv. of phenol, with
90 complete conversion achieved using 5 molar equiv. (Fig. S13). We anticipated a ‘catalyst-free aldol’
91 bioconjugation of this type might be of significant interest in the field due to the simplicity of the
92 phenol probe and were intrigued to note, perhaps unsurprisingly, that precedent for such reactivity
93 already exists in the study of reactive α -oxo aldehydes *in vivo*. These include highly electrophilic

94 glyoxal, methyl glyoxal and 2-deoxyglucosone which are produced endogenously by glycolysis⁵²⁻⁵³ or
 95 exogenously by the Maillard reaction between sugars and amino acids in foods and can react non-
 96 enzymatically with nucleophilic amino residues in proteins.⁵⁴ The resulting modified proteins are
 97 known as advanced glycation end products (AGEs) and their build up is associated with diabetic




Fig. 2 a) Outline of reaction of α -oxo-aldehyde-VARLG **1** with aniline **2** and phenol **3** or **4**, formation of a mixture of stereoisomers is likely and therefore stereochemistry is omitted for clarity here and throughout. Calculated $[M+H]^+$ of product **5** = 814.44 Da. Calculated $[M+H]^+$ of product **6** = 844.45 Da. Inset: LC-MS spectra of the reaction products. b) MS² spectrum of phenol peptide product **7**. The connectivity between phenol **4** and aldehyde **1** is predicted on the basis of precedent established in the reaction between methyl glyoxal and catechins and used from hereon. PB = phosphate buffer.

98 complications and a number of other age-related pathologies,⁵⁵⁻⁵⁷ however AGE formation can be
 99 reduced by polyphenols including catechins and theaflavins present in green and black teas,⁵⁸⁻⁶⁰ which
 100 have been demonstrated to trap these reactive α -oxo-aldehydes in aldol-type reactions under
 101 physiological conditions⁶⁰⁻⁶² akin to those employed here. Notably the substitution was unequivocally
 102 proven to occur between a phenol and alkoxy substituent⁵⁴ (connectivity depicted in **7**, Fig. 2b, and
 103 adopted from herein), and reinforces the reactivity we observe here using 3,5-dimethoxy phenol **4**
 104 and the α -oxo aldehyde peptide **1**.

105 Controlling reaction pathways through pH

106 Having established that both an α -oxo-Mannich and a catalyst-free aldol bioconjugation were taking
 107 place simultaneously at the α -oxo aldehyde centre in pH 6.5 buffer when using both phenol **4** and

108 aniline **2** as reactants, we set out to determine whether the progress through each reaction pathway
 109 could be controlled by changing the pH. The three-component Mannich bioconjugation was previously
 110 reported to have an optimal reactivity observed at pH 5.5-6.5 and poor reactivity observed above pH
 111 8,⁴⁷ with a cyclic transition state proposed at pH 6.5 which simultaneously activated both the
 112 electrophilic imine and the nucleophilic phenol.⁴⁷ On peptides however Mannich reactions have also
 113 been reported to proceed over a much wider pH range, with reactions proceeding at a pH as low as
 114 2.⁶³ Conversely a phenol is more likely to react as a nucleophilic enolate/enol equivalent in a catalyst
 115 free-aldol bioconjugation at more basic pH.^{50-51,64} We therefore opted to incubate the α -oxo aldehyde-
 116 VARLG **1**, aniline **2** (20 equiv.), and phenol **4** (5 equiv.) for 24 h at 37 °C in buffer, at both pH 4.5 and
 117 pH 7.5 (Fig. 3). Notably at pH 4.5, the modified α -oxo-Mannich species **6** was now formed as the major
 118 product with the aldol species **7** the minor byproduct in a reversal of what was previously observed at
 119 pH 6.5 (Fig. 1a), indicating the anticipated preference for the α -oxo-Mannich pathway at more acidic
 120 pH. While at pH 7.5 the aldol product **7** was formed almost exclusively, with only trace α -oxo-Mannich
 121 product formed, indicating a preference for the aldol pathway at more basic pH. This observation was
 122 further supported when the catalyst-free aldol was again performed in the absence of aniline, with
 123 60% relative conversion to aldol product **7** observed at pH 4.5 and complete conversion observed at
 124 pH 7.5 (Fig. S14). Thus screening the same reaction mixture at different pH had enabled us to identify
 125 two novel bioconjugations strategies- a modified α -oxo-Mannich ligation which has the potential to
 126 afford dual functionalised proteins in a single transformation, and a catalyst-free aldol ligation which
 127 has the potential to afford monofunctional bioconjugates at mild neutral pH.

128




Fig. 3 Outline of reaction of α -oxo-aldehyde-VARLG **1** with aniline **2** and phenol **4** at pH 4.5 or pH 7.5. Inset: LC-MS spectra of the reaction products. Calculated $[M+H]^+$ of product **7** = 725.38 Da. Calculated $[M+H]^+$ of product **6** = 844.45 Da.

129

130 **Screening differentially substituted anilines for the α -oxo-Mannich bioconjugation**

131 Next we set out to optimise the conversion of the modified- α -oxo-Mannich at pH 4.5 using phenol **4**
 132 (Fig. 4) by screening a range of differentially substituted anilines **8-21**. Reactions were performed in
 133 duplicate using the α -oxo aldehyde peptide **1** and afforded either starting material **1** (orange in the
 134 bar chart), catalyst-free aldol product **7** (green), or α -oxo-Mannich product **22** (blue). Notably
 135 changing the nature of the aniline significantly affected the balance of the reaction at pH 4.5 and
 136 dictated whether the catalyst-free aldol or the α -oxo-Mannich reaction pathway was followed. For
 137 example, in the presence of electron poor anilines such as 4-nitroaniline **8** no α -oxo-Mannich product
 138 is observed with small amounts of unreacted peptide and aldol product dominating. This was also the
 139 case for anilines **9** and **10** which were substituted with electron withdrawing groups at the ortho
 140 position, wherein conversions to aldol product **22** were similar to that observed for the negative
 141 control [absence of an aniline (-)]. In contrast more basic anilines such as **16-21** which lack electron
 142 withdrawing groups and have pKa values in the 4-5.5 range afforded mostly α -oxo-Mannich product
 143 **22**, with 4-methoxyaniline **21** performing best with ~90% relative conversion. As previously noted
 144 anilines have been extensively used as nucleophilic organocatalysts in hydrazone/oxime
 145 bioconjugations of aldehydes in aqueous conditions,^{39, 46} where the bioconjugations proceed via
 146 attack on a protonated aniline Schiff base intermediate⁶⁵⁻⁶⁶ akin to that expected to form during an α -




Fig. 4 Outline of the α -oxo-Mannich bioconjugation of α -oxo-aldehyde-VARLG **1** (orange in the bar chart) with anilines **8-21** and phenol **4** at pH 4.5, to afford α -oxo-Mannich product **22** (blue) or catalyst-free aldol product **7** (green).

147 oxo-Mannich reaction mechanism.⁶⁵ The most effective of these aniline organocatalysts studied often
148 have a more basic pKa, closer to the pH of the reaction mixture, as this promotes protonation of the
149 aniline Schiff base thus making it more electrophilic. It is therefore unsurprising that at pH 4.5, 4-
150 ethylaniline **18** (pKa ~5.1), aniline **16** (pKa ~4.6),⁶⁵ and 4-methoxyaniline **21** (pKa 5.3)⁶⁵ afford mostly
151 α -oxo-Mannich product. However, 2,4,6-trimethylaniline **11** (pKa ~4.4) affords little α -oxo-Mannich
152 product with aldol product predominating, indicating the situation is likely governed by the interplay
153 between both steric and electronic factors. Overall higher α -oxo-Mannich conversions were observed
154 with electron rich anilines which presumably form more stable Schiff base intermediates. Indeed when
155 comparing the equilibrium LCMS conversion to Schiff base intermediates upon incubation of the α -
156 oxo peptide **1** with either 4-nitroaniline **8**, 2,4,6-trimethylaniline **11**, 3,5-dimethylaniline **13**, aniline **16**
157 or 4-ethylaniline **18** at pH 4.5, a clear trend between higher conversion to the Schiff base and higher
158 α -oxo-Mannich conversion was observed (Fig. S15). Notably an identical aniline screen at pH 7.5
159 afforded negligible α -oxo-Mannich conversions, and aldol conversions of >90% with all anilines (Fig.
160 S16).

161 **Site-selective *N*-terminal and internal α -oxo-Mannich bioconjugation for neoglycoprotein synthesis**

162 Following optimisation studies on peptides we opted to utilise the α -oxo-Mannich procedure for the
163 bioconjugations of proteins. Having established that 4-ethylaniline **18** afforded high conversion to the
164 α -oxo-Mannich products we employed this aniline in combination with phenol **4** for the
165 bioconjugation of the nanobody JVZ007, bearing an *N*-terminal α -oxo aldehyde easily accessed via
166 rapid NaIO₄ oxidation of an *N*-terminal serine or threonine residue³⁷ or transamination of an *N*-
167 terminal glycine.⁶⁷ JVZ007 binds specifically to the prostate specific membrane antigen (PSMA)
168 overexpressed on prostate cancer cell surfaces,⁶⁸ and was successfully modified at pH 4.5 to afford
169 the α -oxo-Mannich product in 68% conversion (Fig. S21), with 32% conversion to the aldol product
170 **23**. As 4-methoxyaniline **21** afforded highest relative conversions to the α -oxo-Mannich product on
171 the peptide we also synthesised a comparable para-derivatised aniline **24** bearing an α -D-mannose
172 sugar. This sugar has potential therapeutic utility against urinary tract infections as an inhibitor of
173 FimH, the type-one pilus subunit on the surface of uropathogenic *E. coli* responsible for adhesion to
174 the urothelium.⁶⁹ The *N*-terminal α -oxo aldehyde JVZ007 could also be modified using this mannose
175 derivatised aniline **24** to afford a neoglycoprotein **25**, affording 64% α -oxo-Mannich product and 36%
176 conversion to the aldol product **23** (Fig. 5a and b).




Fig. 5 a) Neoglycoprotein product **25** of the α -oxo-Mannich bioconjugation of JVZ007 (bearing an N-terminal α -oxo aldehyde) with phenol **4** and mannose aniline **24**. b) Deconvoluted LC-MS spectra showing the α -oxo-Mannich bioconjugation products. Aldol modified JVZ007 **23** calc. 12247, α -oxo-Mannich modified JVZ007 **25** calc. 12500. c) Outline of a two-step *internal* site-selective Pd-mediated decaging/ α -oxo-Mannich bioconjugation to afford sfGFP neoglycoprotein **28**. Pd-mediated decaging of sfGFP-N150ThzK **26**, was followed by α -oxo-Mannich of sfGFP-N150 α -oxo **27** (50 μ M) with phenol **4** (125 equiv.), and mannose aniline **24** (300 equiv.) at pH 5.5 for 20 h. d) Left panel: SDS-PAGE analysis of the reaction. Mw) molecular weight ladder, 1) α -oxo-Mannich bioconjugation, 2) no aniline negative control, 3) no phenol negative control. Right panel: Concanavalin A lectin blot analysis of the reaction. 1) α -oxo-Mannich bioconjugation, 2) no aniline negative control, 3) no phenol negative control.

177

178 We next demonstrated that the α -oxo-Mannich could be also utilised to site-selectively modify an α -
 179 oxo aldehyde incorporated at an *internal* site within superfolder green fluorescent protein (sfGFP).
 180 The aldehyde was quantitatively installed at position 150 of sfGFP using a biocompatible Pd-mediated
 181 decaging (1 equiv. for 1 h at neutral pH) of an incorporated unnatural thiazolidine-lysine (ThzK) amino
 182 acid in sfGFP-N150ThzK **26** (Fig. 5c), recently developed in our lab.^{35,37} The resulting ‘decaged’ internal
 183 aldehyde within sfGFP-N150 α -oxoK **27** was then functionalised via the α -oxo-Mannich using mannose
 184 aniline **24** and 3,5-dimethoxy phenol **4** to afford an internally modified mannose neoglycoprotein **28**.
 185 Although we observed marginally higher conversion to this α -oxo-Mannich neoglycoprotein **28** at pH
 186 4.5 over pH 5.5, we also noted a 4-fold decrease in sfGFP fluorescence observed following incubation
 187 at pH 4.5 (Fig. S23) compared to pH 7.4. However incubation at pH 5.5 only resulted in a 1.6-fold

188 decrease in sfGFP fluorescence, indicating that the α -oxo-Mannich biconjugation is still a suitable
189 method for yielding a site-selectively modified biologically functional sfGFP, despite its sensitivity to
190 acidic pH.⁷⁰ The integrity and accessibility of the mannose aniline on the sfGFP neoglycoprotein surface
191 was further confirmed in a lectin blot using a glycan binding Concanavalin A- Horseradish peroxidase
192 (HRP) conjugate⁷¹ (Fig. 5d right panel, lane 1), with no modification observed in the absence of the
193 mannose aniline **24** (Fig. 5d, right panel, lane 2), or the 3,5-dimethoxy phenol **4** (Fig. 5d, right panel,
194 lane 3).

195 **Optimising mannose neoglycoprotein synthesis**

196 Although the α -oxo-Mannich bioconjugation enabled the construction of neoglycoproteins on both
197 JVZ007 and internally on sfGFP using mannose aniline **24**, competing formation of the catalyst free
198 aldol product limited conversion to the α -oxo-Mannich product in 20 h reactions, particularly in the
199 case of sfGFP (30% conversion to α -oxo-Mannich, 70% catalyst free aldol at pH 4.5, Fig. S25). Having
200 established both the optimal aniline scaffold and pH for the α -oxo-Mannich bioconjugation, we
201 therefore sought to increase reaction conversions through further optimisation of reaction conditions.
202 As we anticipated the bioconjugation would proceed through attack on a protonated aniline Schiff
203 base intermediate,⁶⁵⁻⁶⁶ *vide supra*, we speculated that an increase in the concentration of aniline used
204 in the reaction may also drive formation of the α -oxo-Mannich product over the catalyst free aldol
205 product. To investigate the effect of increasing aniline concentration we utilised the Hydrophilic
206 Acylated Surface Protein A (HASPA) from *Leishmania*, a highly immunogenic protein which is present
207 in all human infective *Leishmania* parasites and a member of the HASP family of proteins which form
208 the basis of a visceral leishmaniasis vaccine currently undergoing clinical trials in humans.⁷² N-terminal
209 α -oxo aldehyde HASPA³⁷ **29** was incubated at pH 4.5 for 20 h with 125 equiv. of 3,5-dimethoxy phenol
210 **4** and an increasing concentration of mannose aniline **24** (75-1000 equiv., Fig. 6a). Using electrospray
211 ionisation Fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICR MS)⁷³ we were
212 able to resolve MS peaks for α -oxo aldehyde HASPA starting material **29**, catalyst free aldol product
213 **30**, and the α -oxo-Mannich HASPA product **31**, enabling accurate determination of relative
214 conversion. In control reactions (Fig. 6b) lacking 3,5-dimethoxy phenol **4** or using a HASPA lacking an
215 α -oxo aldehyde (non-oxidised) no modification occurs, while in the absence of the mannose aniline
216 **24** the catalyst free aldol product **30** is predominantly observed. However, upon the inclusion of 75
217 equiv. of aniline **24** (Fig. 6c) a 53% relative conversion to α -oxo-Mannich product **31** is observed and
218 increases to 58% when the aniline is doubled to 150 equiv., with only 38% relative conversion to
219 catalyst free aldol product **30** observed. This trend continues as the mannose aniline **24** equiv. are
220 increased further (Fig. 6d), with 60% relative to conversion to α -oxo-Mannich **31** and 38% conversion
221 to catalyst free aldol product **30** observed at 300 equiv., and 75% relative conversion to α -oxo-

222 Mannich product **31** when using 1000 equiv. of aniline **24**. These results reinforce the notion that
 223 increased formation of the Schiff base affords higher relative conversion to the α -oxo-Mannich
 224 product over the catalyst free aldol product.

225 We also noted the effect of reaction time on product formation by comparing the relative conversions
 226 of α -oxo aldehyde HASPA **29** using 125 equiv. of 3,5-dimethoxy phenol **4** and 300 equiv. of mannose
 227 aniline **24** at pH 4.5 after 20 h and 6 h (Fig. S32-S33). Unexpectedly we observed a higher 90% relative
 228 conversion to α -oxo-Mannich product **31** (with ~8% catalyst free aldol product **30**) if the reaction was
 229 stopped at 6 h rather than after 20 h (60% α -oxo-Mannich product **31**; 34% catalyst free aldol product
 230 **30**). This trend was also conserved in the bioconjugation of the internal α -oxo aldehyde sfGFP **27** (Fig.
 231 S28) with higher conversions to α -oxo-Mannich product **28** observed when the reaction was stopped
 232 at 6 h, as opposed to 20 h. As the decrease in α -oxo-Mannich product between 6 h and 20 h was
 233 accompanied by an increase in catalyst free aldol product, we hypothesised that the α -oxo-Mannich
 234 product may be breaking down to the catalyst free aldol product down through the release of aniline




Fig. 6 Outline of the optimisation of the α -oxo-Mannich bioconjugation of Leishmania HASPA 33 (50 μ M) at pH 4.5 for 20 h with phenol **4** (125 equiv.) and mannose aniline **24** (75-1000 equiv.) to afford HASPA neoglycoprotein **31**. Deconvoluted ESI-FTICR MS of reaction mixture with b) **a** no aniline or phenol probes, **b** no phenol **4**, **c** no mannose aniline **24**, **d** using non-oxidised Leishmania HASPA; c) **e** phenol **4** (125 equiv.) and mannose aniline **24** (75 equiv.), **f** phenol **4** (125 equiv.) and mannose aniline **24** (100 equiv.), **g** phenol **4** (125 equiv.) and mannose aniline **24** (150 equiv.); d) **h** phenol **4** (125 equiv.) and mannose aniline **24** (200 equiv.), **i** phenol **4** (125 equiv.) and mannose aniline **24** (300 equiv.), **j** phenol **4** (125 equiv.) and mannose aniline **24** (500 equiv.), **k** phenol **4** (125 equiv.) and mannose aniline **24** (1000 equiv.).

235 at pH 4.5. To validate this hypothesis we tested the stability of the α -oxo-Mannich products formed
236 from 3,5-dimethoxy phenol **4** and 4-ethylaniline **18** on both the JVZ007 and HASPA proteins (50 μ M
237 protein concentration) in 0.1 M NaOAc at pH 4.5. Notably, in the absence of any excess aniline in the
238 reaction mixture we observed complete breakdown of both the JVZ007 and HASPA α -oxo-Mannich
239 products to the catalyst free aldol product within 6 h at acidic pH (Fig. S34-S36), indicating that to
240 achieve optimal conversions to α -oxo-Mannich product it is preferable to use an excess of aniline
241 probe over a shorter reaction time.

242

243 **Optimising the catalyst-free aldol bioconjugation**

244 Although competing formation and/or breakdown to the aldol product when attempting to perform
245 multicomponent bioconjugations using the α -oxo-Mannich was problematic, this highlighted the
246 potential utility of the catalyst-free aldol as a standalone bioconjugation capable of producing
247 monofunctionalised bioconjugates. From our initial experiments with α -oxo aldehyde VARLG **1** at pH
248 6.5 using both 3,5-dimethoxy phenol **4** and 4-methoxy phenol **3** (Fig. 2) it was clear that the both
249 compounds show significantly different reactivity towards ligation with the peptide. These results
250 suggested that the substitution on the aromatic ring may impact the efficiency of the catalyst-free
251 aldol bioconjugation. Therefore, to dissect the intricacies of the ligation, a further series of small
252 molecule aromatic probes **32-37** were screened for their activity in modification of α -oxo aldehyde
253 VARLG **1** (Figure 7). Using a 5-fold excess of probe over peptide at pH 7.5 we noted that when using
254 electron rich aromatics which lacked a phenol substituent such as 1,3,5-trimethoxybenzene **32** and
255 1,3-dimethoxybenzene **35**, no bioconjugation occurred but when the phenol substituent(s) were
256 reintroduced as in 3,5-dimethoxy phenol **4** or 1,3-resorcinol **35** complete relative conversion to the
257 catalyst-free aldol VARLG product **38** was observed. This confirmed that the presence of the phenol
258 group is essential for conversion, akin to the observations previously made in bioconjugations
259 between electron rich aromatics and electrophilic selenocysteine residues,⁵¹ and reinforcing the
260 hypothesis that the phenol may act as an enol/enolate equivalents as has previously been reported in
261 reaction with aldehydes in water.⁵⁰ When less electron rich dimethyl phenol **37** is used formation of
262 the aldol product **38** is observed but at much lower relative conversion, and when an electron
263 withdrawing ortho carboxylic acid is introduced in phenol **34** no conversion is observed. However on
264 the introduction of a second phenol in to this scaffold in the case of diphenol **36** 49% conversion to
265 the catalyst free aldol product **38** is observed suggesting that an intramolecular hydrogen bond

266 between the phenol and adjacent carbonyl in **34** may interfere with the bioconjugation, but can be
 267 compensated for by the introduction of another phenol elsewhere in the aromatic ring.




Fig. 7 Outline of the catalyst-free aldol reaction of α -oxo-aldehyde-VALRG **1** (1 mM) with aromatics **4**, **32-37** (5 equiv.) at pH 7.5 for 24 h, demonstrating increased conversion to aldol product **38** upon the introduction of phenol substituents in the aromatic ring.

268 Catalyst-free aldol bioconjugation of proteins

269 Subsequently we demonstrated the catalyst-free aldol bioconjugation using 3,5-dimethoxy phenol
 270 probe **4** was also operative on proteins bearing α -oxo aldehyde residues, including myoglobin **39**,⁶⁷
 271 Leishmania HASPA **29**, and JVZ007 **40** (Fig. 8a-c), with complete conversion to the aldol products
 272 observed within 1 h. However, to be of practical utility as a bioconjugation reaction the catalyst-free
 273 aldol would need to also be operative using modified phenol probes, thus enabling the introduction
 274 of new non-proteinogenic functionality into the protein target. We therefore synthesized a 1,3-
 275 resorcinol capped probe **43** containing a dansyl tag to enable the fluorescent labeling of a protein
 276 using the catalyst free aldol and screened increasing equivalents of this probe in the reaction with the
 277 HASPA protein **31** (Fig. 8d). SDS-PAGE and LC-MS analysis confirmed successful fluorescent
 278 modification of HASPA **29** when using >100 equiv. of probe thus demonstrating that simple phenol
 279 scaffolds can be used as the basis of complex functional probes for bioconjugation.




Fig. 8 Catalyst-free aldol reactions using phenol **4** on α -oxo aldehyde bearing proteins a) myoglobin **39**, b) *Leishmania* HASPA **29**, and c) JVZ007 **40**. Inset right: Deconvoluted LC-MS analysis of the respective reaction products. d) Catalyst-free aldol reaction of *Leishmania* HASPA **29** with fluorescent phenol **43**. Inset right: Deconvoluted LC-MS analysis of the reaction products. d) Inset below: SDS-PAGE analysis of the reaction with coomassie staining (left panel) and fluorescent visualization (right panel): 1) 50 equiv. **43**; 2) 100 equiv. **43**; 3) 250 equiv. **43**; 4) No probe **43** control; 5) Non-oxidised HASPA + **43** control. Substitution in **44** may occur *ortho/ortho* to both phenol substituents or *ortho/para*. HASPA migrates aberrantly on SDS-PAGE due to its hydrophilicity⁷³ and migration is affected by bioconjugation.³⁷

280

281 We also considered whether natural products containing phenols such as flavonoids, which have been
 282 shown to capture methyl glyoxal in water,⁵⁹⁻⁶² may also be capable of undergoing catalyst-free aldol
 283 ligation to proteins. We thus screened the plant secondary metabolite catechin **45** in reactions with
 284 the prostate cancer targeting nanobody **40** at pH 7.5 and observed full conversion to the aldol product
 285 **48** within 1 h (Fig. 9a). Additionally, we showed that the glucose bearing flavonoid phloridzin **47**, which
 286 is a competitive inhibitor of sodium-glucose cotransporter (SLGTs), was also capable of modifying the
 287 nanobody **40** to afford an aldol product **48** at pH 7.5 within 4 h (Fig. 9b). Once again the accessibility

288 of the glycan on the neoglycoprotein **48** surface was confirmed in a lectin blot using ConA-HRP (Fig.
 289 9c). Notably SLGTs are functionally expressed in (prostate) cancer cells⁷⁵ to meet the increased
 290 metabolic demands for glucose in tumours⁷⁶ and therapeutic blockade with SLGT inhibitors can
 291 therefore lead to tumour necrosis.⁷⁷ However the therapeutic use of phloridzin is limited because as
 292 a potential treatment for type-2 diabetes it also non-selectivity targets SLGTs in the intestine and the
 293 kidney,⁷⁸ and additionally has poor oral bioavailability⁷⁹ due to glycoside hydrolysis by β -galactosidase




Fig. 9 Catalyst-free aldol bioconjugation of α -oxo aldehyde bearing JVZ007 **40** with a) catechin **45** and b) phloridzin **47**. Inset right: Deconvoluted LC-MS analysis of the respective reaction products. Catechin modified JVZ007 **46** calc. 12383; phloridzin modified JVZ007 **48** calc. 12529. Substitution in **46** and **48** is predicted on the basis of precedent established in the reaction between methyl glyoxal and catechins,⁵⁴ notably substitution in **48** may occur *para* or *ortho* to the glucose substituents. c) Concanavalin A lectin blot of 1) α -oxo JVZ007 **40**, 1.5 μ g/mL; 2) phloridzin modified JVZ007 **48**, 0.5 μ g/mL; 3) phloridzin modified JVZ007 **48**, 1 μ g/mL; 4) phloridzin modified JVZ007 **48**, 1.5 μ g/mL.

294 enzymes such as lactase. Our demonstration that phloridzin can easily undergo bioconjugation to a
 295 protein scaffold could therefore stimulate further studies into whether such constructs may have
 296 enhanced stability to glycosidases, and enhanced selectivity for inhibition of tumour SLGTs via
 297 antibody targeted delivery.

298

299 Mechanistic hypothesis and catalyst-free aldol bioconjugate stability

300 Based on the aforementioned experimental observations we formulated a mechanistic pathway (Fig.
 301 10) for the formation of both the Mannich and aldol products and propose the α -oxo-Mannich
 302 bioconjugation initially proceeds through the formation of the protonated aniline Schiff base
 303 intermediate **49**. It is likely the equilibrium concentration of this intermediate in pH 4.5 buffer is
 304 governed by both the concentration of aniline present in the reaction mixture (see Fig. 6), and the

305 electron donating ability of the aniline (see Fig. 4). The Schiff base **49** then undergoes attack by the
306 phenol to generate the α -oxo-Mannich product **50**. The competing catalyst-free aldol bioconjugation
307 can also take place at pH 4.5 (and pH 7.5) and we propose the product **51** results from a direct aldol-
308 type attack of the phenol on the α -oxo aldehyde **52**, wherein the phenol substituent is essential for
309 conversion (see Fig. 7). We also observed that the α -oxo-Mannich product **50** undergoes breakdown
310 to the catalyst-free aldol product at pH 4.5 within 6 h and hypothesise this occurs via the intermediate
311 carbocation **53** which can be trapped by water to afford product **51**, or alternatively excess phenol to
312 afford **54** which was identified as a minor byproduct. To confirm that the α -oxo-Mannich product **50**
313 was formed via the Schiff base **49** and not by aniline attack on carbocation **53** following an initial
314 catalyst-free aldol reaction, we also incubated purified VARLG-aldol product **7** with mannose aniline
315 **24** in pH 4.5 buffer for 20 h, and observed no conversion from aldol to α -oxo-Mannich product over
316 the course of the reaction (Fig. S49), unequivocally demonstrating that Mannich product formation
317 does not result from initial aldol product formation. This may be because under the conditions of the
318 reaction the (protonated) aniline nucleophile is unable to outcompete water in attack on carbocation
319 **53**. In the absence of aniline the catalyst-free aldol reaction proceeds at pH 4.5 but more efficiently at
320 pH 7.5 (Fig. S14) to afford the aldol bioconjugate within as little as 1 h. However, when we tested the
321 stability of the aldol bioconjugates by re-incubating purified JVZ007-aldol bioconjugate **23** in buffer at
322 50 μ M concentration, we were surprised to observe that while the conjugate was stable at pH 4.5, at
323 pH 7.5 breakdown to the JVZ007 α -oxo aldehyde starting material **40** (~32%) occurred within 6 h (Fig.
324 S51). As it is well established that the redox potential of phenols with adjacent proton acceptors are
325 lower than that of simple phenols,⁸⁰ we hypothesised this breakdown (depicted in Fig 10 as **51** to **53**)
326 may result from an initial one-electron oxidation of the electron rich phenol component of the aldol
327 product facilitated by intramolecular H-bonding interactions at pH 7.5. Indeed the ubiquitous enzyme
328 complex Photosystem II contains a Tyr₂-His190 hydrogen bonding pair in its reaction centre which
329 undergoes facile proton-coupled electron transfer (PCET) resulting in the generation of a neutral
330 phenolic radical,⁸¹ and a number of biomimetic models of this system have been constructed⁸²⁻⁸³
331 which resemble elements of the aldol products described here. Notably these models have been
332 shown to undergo facile concerted one-electron two-proton transfer processes. Therefore to explore
333 whether a one-electron oxidation may trigger breakdown we re-screened the stability of JVZ007-aldol
334 bioconjugate **23** at pH 7.5 in the presence of antioxidant sodium ascorbate.⁸⁴ Whilst breakdown of the
335 aldol bioconjugate **23** to JVZ007 α -oxo aldehyde **40** was still observed in the presence of 1 mM
336 ascorbate, at a higher concentration of 6 mM the aldol bioconjugate **23** appeared to show reduced
337 breakdown over 6h (Fig. S52). Although electrochemical, spectroscopic and DFT studies will be

338 undoubtedly be required to unequivocally prove the hypothesised mechanism, this result tentatively
 339 suggests the aldol product may be unstable at low concentrations as a result of phenol oxidation.




Fig. 10 Proposed mechanistic rationale for formation and breakdown of both the α -oxo-Mannich product **50** and the catalyst-free aldol product **51**.

340

341 CONCLUSIONS

342 In conclusion we have developed two novel bioconjugation reactions using an α -oxo aldehyde handle
 343 that can be site-selectively installed into biomolecules. In the presence of both phenol and aniline
 344 nucleophiles the α -oxo-Mannich and catalyst-free aldol bioconjugations compete with each other for
 345 this unique electrophile, but through judicious choice of pH, substrates, and optimisation of reaction
 346 conditions formation of the multicomponent α -oxo-Mannich products can be favoured. We also
 347 demonstrated that the Mannich products breakdown to afford the catalyst-free aldol product at both
 348 neutral and acidic pH. However, the rate of this breakdown reaction is likely governed by both the
 349 electron donating ability of the phenol and the basicity of the aniline, potentially providing a tuneable
 350 scaffold for the controllable release of small molecule cargo from a protein delivery system in future
 351 studies.

352 In the absence of aniline, phenols react cleanly and rapidly with α -oxo aldehyde containing
353 proteins at pH 7.5, akin to reactivity previously observed in the sequestration of AGE precursors
354 glyoxal and methyl glyoxal by green/black tea polyphenols. Intriguingly however, when our catalyst-
355 free aldol bioconjugate was incubated in the absence of the electron rich phenol **4**, we observed
356 breakdown to the α -oxo aldehyde starting material at pH 7.5, but none at pH 4.5. This process may
357 be a result of one-electron oxidation of the phenol and highlights a need to revisit the study of tea
358 polyphenol sequestrations of reactive α -oxo aldehydes *in vitro* and *in vivo*, particularly the stability of
359 the conjugates in the absence of polyphenol. Additionally, the instability observed for both the aldol
360 and α -oxo-Mannich bioconjugates may limit the *in vivo* utility of the conjugates due to potential
361 premature breakdown in the bloodstream at physiological pH, which in the case of antibody-drug
362 conjugates can lead to toxicity.⁸⁵ However, it is likely the nature of the phenol component within the
363 catalyst-free aldol bioconjugate could have a direct effect on its stability, suggesting that like the α -
364 oxo-Mannich, if pH stability could be increased then the catalyst-free aldol bioconjugation may afford
365 a tuneable scaffold which could potentially be leveraged in the future for oxidative release of small
366 molecules from proteins. For example cancer cells have higher levels of reactive oxygen species due
367 to increased metabolic activity and a number other oncogenic processes,⁸⁶ and thus could conceivably
368 provide an ideal environment for selective release of phloridzin, or other SLGT inhibitors from the
369 prostate cancer targeting nanobody bioconjugate **48** constructed here.

370

371 **METHODS**

372 **General procedures and materials**

373 All solvents were dried prior to use according to standard methods, with the exception of solvents
374 used for flash chromatography purposes, where GPR-grade solvents were used. All commercially
375 available reagents were used as received. Analytical grade reagents were supplied by Sigma-Aldrich,
376 Fisher Scientific, VWR International, Carbosynth, Alfa aesar and TCI. All solution-phase reactions were
377 carried out under a dry nitrogen atmosphere using oven-dried glassware unless otherwise stated. All
378 concentrations were performed in vacuo unless otherwise stated. Thin layer chromatography was
379 carried out on Merck silica gel 60 F254 pre-coated aluminium foil sheets and these were visualised
380 using UV light (254 nm) or charred following immersion in 5% sulphuric acid in methanol. Hydrophilic
381 acylated surface protein A (HASPA) G1S mutant was prepared exactly as previously described.³⁷
382 sfGFP(N150Thz) was prepared exactly as previously described.³⁵ Myoglobin from equine heart
383 (M1882) was purchased from Sigma-Aldrich and used without further purification.

384

385 **NMR**

386 ¹H and ¹³C NMR spectra were measured at 500 MHz and 126 MHz respectively using a Bruker 500-
387 MR spectrometer at the University York Centre for Magnetic Resonance, using Me₄Si as an internal
388 standard when using chloroform d. Multiplicities are given as singlet (s), doublet (d) doublet of
389 doublets (dd), doublet of doublet of doublets (ddd) or multiplet (m). Resonances were assigned using
390 HH-COSY and CH-HSQC. All NMR chemical shifts (δ) were recorded in pp and coupling constants (J) are
391 reported in Hz. Topspin 4.0.6 was primarily used for processing the spectral data.

392

393 **FTIR and optical rotations**

394 Fourier transform infrared (FTIR) spectra were recorded on a PerkinElmer UATR 2 spectrometer using
395 the attenuated total reflectance (ATR) technique. (ESI) Optical rotations were measured using a
396 Bellingham and Stanley ADP 450 Automatic Digital Peltier Controlled Polarimeter equipped with a 589
397 nm LED. Concentration is denoted as c and was calculated as grams per 100 millilitres (g / 100 mL)
398 whereas the solvent is indicated in parenthesis (c, solvent).

399

400 **Mass spectrometry**

401 Small-molecule high resolution mass spectrometry (HRMS) data were obtained at room temperature
402 on a Bruker Daltonics microTOF mass spectrometer coupled to an Agilent 1200 series LC system.

403 High Performance Liquid Chromatography-Electrospray Ionisation Mass Spectrometry (LC-MS) was
404 accomplished using a Dionex UltiMate[®] 3000 LC system (ThermoScientific) equipped with an
405 UltiMate[®] 3000 Diode Array Detector (probing 250-400 nm) in line with a Bruker HCTultra ETD II
406 system (Bruker Daltonics), using Chromeleon[®] 6.80 SR12 software (ThermoScientific), Compass 1.3
407 for esquire HCT Build 581.3, esquireControl version 6.2, Build 62.24 software (Bruker Daltonics), and
408 Bruker compass HyStar 3.2-SR2, HyStar version 3.2, Build 44 software (Bruker Daltonics) at The
409 University York Centre of Excellence in Mass Spectrometry (CoEMS). All mass spectrometry was
410 conducted in positive ion mode unless stated otherwise. Data analysis was performed using ESI
411 Compass 1.3 DataAnalysis, Version 4.1 software (Bruker Daltonics). Prior to analysis by LC-MS, peptide
412 or protein ligation mixture was diluted 1:3 in water and then further diluted 1:1 in acetonitrile with 1
413 % (v/v) formic acid. Peptide samples were analysed using an Accucore[™] C18 2.6 μ m column (50 x 2.1
414 mm) (ThermoScientific). Water with 0.1 % (v/v) formic acid (solvent A) and acetonitrile with 0.1 %
415 (v/v) formic acid (solvent B) were used as the mobile phase at a flow rate of 0.3 mL/min at room
416 temperature (RT). A multi-step gradient of 6.5 min was programmed as follows: 90% A for 0.5 min,
417 followed by a linear gradient to 95% B over 3.5 min, followed by 95% B for an additional 0.5 min. A
418 linear gradient to 95% A was used to re-equilibrate the column Under these conditions all peptides
419 typically eluted between 2-5 min. Protein samples were analysed without the use of a column at RT.

420 Water with 0.1 % (v/v) formic acid (solvent A) and acetonitrile with 0.1 % (v/v) formic acid (solvent B)
421 were used as the mobile phase at a 1:1 ratio over the course of 3 min as follows: 0.05 mL/min to 0.25
422 mL/min for 1 min, 0.025 mL/min for 1 min, followed by 1.0 mL/min for 1 min. Under these conditions,
423 all proteins typically eluted between 0.1-1.5 min.

424 Protein electrospray ionisation (ESI) mass spectra were obtained on a Bruker Solarix XR 9.4 T FTICR
425 mass spectrometer. Samples were desalted and analysed at a final concentration of 0.3-10 μ M in
426 50:50:1 (v/v) H₂O:MeCN:FA. Mass spectrometry data analysis was performed using ESI Compass 1.3
427 DataAnalysis, Version 4.4 software (Bruker Daltonics).

428

429 **Determination of bioconjugation relative conversion**

430 For peptide bioconjugations, conversion from starting material to the desired product (relative
431 conversion, %) was calculated by analysing the peak intensities of starting material and product
432 species obtained after LC-MS analysis. For protein bioconjugations mass spectra were first
433 deconvoluted, then conversion from starting material to the desired product was calculated by
434 analysing the peak intensities of the starting material and product species.

435

436 **Solid Phase Peptide Synthesis (SPPS)**

437 Peptides were synthesised via manual solid phase peptide synthesis (SPPS) using an in-situ
438 neutralisation/HCTU activation procedure for Fmoc chemistry on an H-Gly-2- ClTrt resin (Sigma) using
439 Fmoc protected amino acids as described below:

440 Preloaded resin preparation. The preloaded 2-chlorotrityl resin was weighed out into a 2 mL SPPS
441 cartridge fitted with a PTFE stopcock, swollen in DMF for 30 min and then filtered.

442 Amino acid coupling. DIPEA (11.0 eq.) was added to a solution of amino acid (5.0 eq.) and HCTU (5.0
443 eq.) dissolved in the minimum volume of DMF and the solution added to the resin. The reaction
444 mixture was gently agitated by rotation for 1 h, and the resin filtered off and washed with DMF (3 \times 2
445 min with rotation).

446 Fmoc deprotection. A solution of 20% piperidine in DMF was added to the resin and gently agitated
447 by rotation for 2 minutes. The resin was filtered off and repeated four more times, followed by washes
448 with DMF (5 \times 2 min with rotation).

449 Cleavage and Isolation. Resins containing full synthesised peptides were washed with DCM (3 \times 2 min
450 with rotation) and MeOH (3 \times 2 min with rotation). The resin was dried on a vacuum manifold and
451 further dried on a high vacuum line overnight. A solution of cleavage cocktail 95:2.5:2.5 (v/v)
452 TFA:H₂O:triisopropylsilane was then added to the resin, and the resulting mixture was gently agitated
453 by rotation for 60 min. The reaction mixture was drained into ice-cold Et₂O and centrifuged at 6000

454 rpm at 4 °C until pelleted (ca. 5-10 min). The supernatant was carefully decanted and subsequently
455 resuspended, centrifuged and supernatant decanted three more times. The precipitated peptide
456 pellet was then either dissolved 10% MeCN or in 10% aq. AcOH and lyophilised. The desired peptide
457 was then further purified via size-exclusion chromatography (Sephadex LH-20 in water), and fractions
458 containing pure, desired peptide were lyophilised and stored at -20 °C until required.

459

460 **SUPPORTING INFORMATION**

461

462 Supporting information figures, bioconjugation experimental protocols and characterization, protein
463 purification and characterization, small molecule synthesis and characterization, and lectin blots.

464

465 **AUTHOR INFORMATION**

466 Corresponding Author Email: martin.fascione@york.ac.uk

467

468 **ACKNOWLEDGEMENTS**

469 We thank E. Bergstrom and The York Centre of Excellence in Mass Spectrometry. The York Centre of
470 Excellence in Mass Spectrometry was created thanks to a major capital investment through Science
471 City York, supported by Yorkshire Forward with funds from the Northern Way Initiative, and
472 subsequent support from EPSRC (EP/K039660/1; EP/M028127/1). This work was supported by The
473 University of York, the EPSRC (PhD award [1944852] to N. Hatton) and EP/P030653/1, EP/S013741/1,
474 EP/V044303/1) and the BBSRC (BB/M02847X/1). C. Mahon is a grateful recipient of a Marie
475 Sklodowska-Curie Global Fellowship from the European Union's Horizon 2020 Research and
476 Innovation Programme under the Marie Sklodowska-Curie grant agreement No. 702927. pBAD-sfGFP
477 150TAG was a gift from R. Mehl (Addgene plasmid # 85483) under MTA, pEVOL PyIRS WT was a kind
478 gift from E. Lemke (EMBL Heidelberg) under MTA.

479

480

481 **REFERENCES**

482

- 483 1. Boutureira, O.; Bernardes, G. J. L., Advances in Chemical Protein Modification. *Chem. Rev.*
484 **2015**, *115* (5), 2174-2195.
- 485 2. Spicer, C. D.; Davis, B. G., Selective chemical protein modification. *Nat. Commun.* **2014**, *5* (1),
486 4740.

- 487 3. Gupta, V.; Bhavanasi, S.; Quadir, M.; Singh, K.; Ghosh, G.; Vasamreddy, K.; Ghosh, A.; Siahaan,
488 T. J.; Banerjee, S.; Banerjee, S. K., Protein PEGylation for cancer therapy: bench to bedside. *J. Cell*
489 *Commun. Signal.* **2019**, *13* (3), 319-330.
- 490 4. Fee, C. J., Size comparison between proteins PEGylated with branched and linear
491 poly(ethylene glycol) molecules. *Biotechnol. Bioeng.* **2007**, *98* (4), 725-731.
- 492 5. Agarwal, P.; Beahm, B. J.; Shieh, P.; Bertozzi, C. R., Systemic Fluorescence Imaging of Zebrafish
493 Glycans with Bioorthogonal Chemistry. *Angew. Chem. Int. Ed.* **2015**, *54* (39), 11504-11510.
- 494 6. Baskin, J. M.; Dehnert, K. W.; Laughlin, S. T.; Amacher, S. L.; Bertozzi, C. R., Visualizing
495 enveloping layer glycans during zebrafish early embryogenesis. *Proc. Nat. Acad. Sci. U.S.A.* **2010**, *107*
496 (23), 10360.
- 497 7. Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; Agard, N. J.; Chang, P. V.; Miller, I. A.; Lo, A.; Codelli,
498 J. A.; Bertozzi, C. R., Copper-free click chemistry for dynamic in vivo imaging. *Proc. Nat. Acad. Sci. U.S.A.*
499 **2007**, *104* (43), 16793.
- 500 8. Saxon, E.; Bertozzi, C. R., Cell Surface Engineering by a Modified Staudinger Reaction. *Science*
501 **2000**, *287* (5460), 2007.
- 502 9. Trads, J. B.; Tørring, T.; Gothelf, K. V., Site-Selective Conjugation of Native Proteins with DNA.
503 *Acc. Chem. Res.* **2017**, *50* (6), 1367-1374.
- 504 10. Bilyard, M. K.; Bailey, H. J.; Raich, L.; Gafitescu, M. A.; Machida, T.; Iglésias-Fernández, J.; Lee,
505 S. S.; Spicer, C. D.; Rovira, C.; Yue, W. W. *et al.*, Palladium-mediated enzyme activation suggests
506 multiphase initiation of glycogenesis. *Nature* **2018**, *563* (7730), 235-240.
- 507 11. Raj, R.; Lercher, L.; Mohammed, S.; Davis, B. G., Synthetic Nucleosomes Reveal that
508 GlcNAcylation Modulates Direct Interaction with the FACT Complex. *Angew. Chem. Int. Ed.* **2016**, *55*
509 (31), 8918-8922.
- 510 12. Parsons, T. B.; Struwe, W. B.; Gault, J.; Yamamoto, K.; Taylor, T. A.; Raj, R.; Wals, K.;
511 Mohammed, S.; Robinson, C. V.; Benesch, J. L. P. *et al.*, Optimal Synthetic Glycosylation of a
512 Therapeutic Antibody. *Angew. Chem. Int. Ed.* **2016**, *55* (7), 2361-2367.
- 513 13. van Kasteren, S. I.; Kramer, H. B.; Jensen, H. H.; Campbell, S. J.; Kirkpatrick, J.; Oldham, N. J.;
514 Anthony, D. C.; Davis, B. G., Expanding the diversity of chemical protein modification allows post-
515 translational mimicry. *Nature* **2007**, *446* (7139), 1105-1109.
- 516 14. Macmillan, D.; Bill, R. M.; Sage, K. A.; Fern, D.; Flitsch, S. L., Selective in vitro glycosylation of
517 recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin.
518 *Chem. Biol.* **2001**, *8* (2), 133-145.
- 519 15. Schlatzer, T.; Kriegesmann, J.; Schröder, H.; Trobe, M.; Lembacher-Fadum, C.; Santner, S.;
520 Kravchuk, A. V.; Becker, C. F. W.; Breinbauer, R., Labeling and Natural Post-Translational Modification
521 of Peptides and Proteins via Chemoselective Pd-Catalyzed Prenylation of Cysteine. *J. Am. Chem. Soc.*
522 **2019**, *141* (37), 14931-14937.
- 523 16. Weng, Y.; Song, C.; Chiang, C.-W.; Lei, A., Single electron transfer-based peptide/protein
524 bioconjugations driven by biocompatible energy input. *Commun. Chem.* **2020**, *3* (1), 171.
- 525 17. Josephson, B.; Fehl, C.; Isenegger, P. G.; Nadal, S.; Wright, T. H.; Poh, A. W. J.; Bower, B. J.;
526 Giltrap, A. M.; Chen, L.; Batchelor-McAuley, C. *et al.*, Light-driven post-translational installation of
527 reactive protein side chains. *Nature* **2020**, *585* (7826), 530-537.
- 528 18. Lobba, M. J.; Fellmann, C.; Marmelstein, A. M.; Maza, J. C.; Kissman, E. N.; Robinson, S. A.;
529 Staahl, B. T.; Urnes, C.; Lew, R. J.; Mogilevsky, C. S. *et al.*, Site-Specific Bioconjugation through Enzyme-
530 Catalyzed Tyrosine-Cysteine Bond Formation. *ACS Cent. Sci.* **2020**, *6* (9), 1564-1571.
- 531 19. Kim, J.; Li, B. X.; Huang, R. Y. C.; Qiao, J. X.; Ewing, W. R.; MacMillan, D. W. C., Site-Selective
532 Functionalization of Methionine Residues via Photoredox Catalysis. *J. Am. Chem. Soc.* **2020**, *142* (51),
533 21260-21266.
- 534 20. Dhanjee, H. H.; Saebi, A.; Buslov, I.; Loftis, A. R.; Buchwald, S. L.; Pentelute, B. L., Protein-
535 Protein Cross-Coupling via Palladium-Protein Oxidative Addition Complexes from Cysteine Residues.
536 *J. Am. Chem. Soc.* **2020**, *142* (20), 9124-9129.

- 537 21. Zhang, C.; Vinogradova, E. V.; Spokoyny, A. M.; Buchwald, S. L.; Pentelute, B. L., Arylation
538 Chemistry for Bioconjugation. *Angew. Chem. Int. Ed.* **2019**, *58* (15), 4810-4839.
- 539 22. Taylor, M. T.; Nelson, J. E.; Suero, M. G.; Gaunt, M. J., A protein functionalization platform
540 based on selective reactions at methionine residues. *Nature* **2018**, *562* (7728), 563-568.
- 541 23. Bloom, S.; Liu, C.; Kölmel, D. K.; Qiao, J. X.; Zhang, Y.; Poss, M. A.; Ewing, W. R.; MacMillan, D.
542 W. C., Decarboxylative alkylation for site-selective bioconjugation of native proteins via oxidation
543 potentials. *Nat. Chem.* **2018**, *10* (2), 205-211.
- 544 24. Lin, S.; Yang, X.; Jia, S.; Weeks, A. M.; Hornsby, M.; Lee, P. S.; Nichiporuk, R. V.; Iavarone, A. T.;
545 Wells, J. A.; Toste, F. D. *et al.*, Redox-based reagents for chemoselective methionine bioconjugation.
546 *Science* **2017**, *355* (6325), 597.
- 547 25. Zhang, C.; Welborn, M.; Zhu, T.; Yang, N. J.; Santos, M. S.; Van Voorhis, T.; Pentelute, B. L., π -
548 Clamp-mediated cysteine conjugation. *Nat. Chem.* **2016**, *8* (2), 120-128.
- 549 26. Rosen, C. B.; Francis, M. B., Targeting the N terminus for site-selective protein modification.
550 *Nat. Chem. Biol.* **2017**, *13* (7), 697-705.
- 551 27. Dadová, J.; Galan, S. R. G.; Davis, B. G., Synthesis of modified proteins via functionalization of
552 dehydroalanine. *Curr. Opin. Chem. Biol.* **2018**, *46*, 71-81.
- 553 28. Bhushan, B.; Lin, Y. A.; Bak, M.; Phanumartwiwath, A.; Yang, N.; Bilyard, M. K.; Tanaka, T.;
554 Hudson, K. L.; Lercher, L.; Stegmann, M. *et al.*, Genetic Incorporation of Olefin Cross-Metathesis
555 Reaction Tags for Protein Modification. *J. Am. Chem. Soc.* **2018**, *140* (44), 14599-14603.
- 556 29. McKay, Craig S.; Finn, M. G., Click Chemistry in Complex Mixtures: Bioorthogonal
557 Bioconjugation. *Chem. Biol.* **2014**, *21* (9), 1075-1101.
- 558 30. Blackman, M. L.; Royzen, M.; Fox, J. M., Tetrazine Ligation: Fast Bioconjugation Based on
559 Inverse-Electron-Demand Diels–Alder Reactivity. *J. Am. Chem. Soc.* **2008**, *130* (41), 13518-13519.
- 560 31. Spears, R. J.; Fascione, M. A., Site-selective incorporation and ligation of protein aldehydes.
561 *Org. Biomol. Chem.* **2016**, *14* (32), 7622-7638.
- 562 32. El-Mahdi, O.; Melnyk, O., α -Oxo Aldehyde or Glyoxylyl Group Chemistry in Peptide
563 Bioconjugation. *Bioconjug. Chem.* **2013**, *24* (5), 735-765.
- 564 33. Bi, X.; Pasunooti, K. K.; Lescar, J.; Liu, C.-F., Thiazolidine-Masked α -Oxo Aldehyde Functionality
565 for Peptide and Protein Modification. *Bioconjug. Chem.* **2017**, *28* (2), 325-329.
- 566 34. Brabham, R. L.; Keenan, T.; Husken, A.; Bilsborrow, J.; McBerney, R.; Kumar, V.; Turnbull, W.
567 B.; Fascione, M. A., Rapid sodium periodate cleavage of an unnatural amino acid enables unmasking
568 of a highly reactive α -oxo aldehyde for protein bioconjugation. *Org. Biomol. Chem.* **2020**, *18* (21),
569 4000-4003.
- 570 35. Brabham, R. L.; Spears, R. J.; Walton, J.; Tyagi, S.; Lemke, E. A.; Fascione, M. A., Palladium-
571 unleashed proteins: gentle aldehyde decaging for site-selective protein modification. *Chem. Commun.*
572 **2018**, *54* (12), 1501-1504.
- 573 36. Mahesh, S.; Adebomi, V.; Muneeswaran, Z. P.; Raj, M., Bioinspired Nitroalkylation for Selective
574 Protein Modification and Peptide Stapling. *Angew. Chem. Int. Ed.* **2020**, *59* (7), 2793-2801.
- 575 37. Spears, R. J.; Brabham, R. L.; Budhadev, D.; Keenan, T.; McKenna, S.; Walton, J.; Brannigan, J.
576 A.; Brzozowski, A. M.; Wilkinson, A. J.; Plevin, M. *et al.*, Site-selective C–C modification of proteins at
577 neutral pH using organocatalyst-mediated cross aldol ligations. *Chem. Sci.* **2018**, *9* (25), 5585-5593.
- 578 38. Zhang, L.; Tam, J. P., Thiazolidine Formation as a General and Site-Specific Conjugation
579 Method for Synthetic Peptides and Proteins. *Analytical Biochemistry* **1996**, *233* (1), 87-93.
- 580 39. Kölmel, D. K.; Kool, E. T., Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis.
581 *Chem. Rev.* **2017**, *117* (15), 10358-10376.
- 582 40. Larsen, D.; Pittelkow, M.; Karmakar, S.; Kool, E. T., New Organocatalyst Scaffolds with High
583 Activity in Promoting Hydrazone and Oxime Formation at Neutral pH. *Org. Lett.* **2015**, *17* (2), 274-277.
- 584 41. Larsen, D.; Kietrys, A. M.; Clark, S. A.; Park, H. S.; Ekebergh, A.; Kool, E. T., Exceptionally rapid
585 oxime and hydrazone formation promoted by catalytic amine buffers with low toxicity. *Chem. Sci.*
586 **2018**, *9* (23), 5252-5259.

587 42. Trausel, F.; Maity, C.; Poolman, J. M.; Kouwenberg, D. S. J.; Versluis, F.; van Esch, J. H.; Eelkema,
588 R., Chemical signal activation of an organocatalyst enables control over soft material formation. *Nat.*
589 *Commun.* **2017**, *8* (1), 879.

590 43. Zhou, Y.; Piergentili, I.; Hong, J.; van der Helm, M. P.; Macchione, M.; Li, Y.; Eelkema, R.; Luo,
591 S., Indoline Catalyzed Acylhydrazone/Oxime Condensation under Neutral Aqueous Conditions. *Org.*
592 *Lett.* **2020**, *22* (15), 6035-6040.

593 44. Trausel, F.; Fan, B.; van Rossum, S. A. P.; van Esch, J. H.; Eelkema, R., Aniline Catalysed
594 Hydrazone Formation Reactions Show a Large Variation in Reaction Rates and Catalytic Effects. *Adv.*
595 *Synth. Cat.* **2018**, *360* (13), 2571-2576.

596 45. Drienovská, I.; Mayer, C.; Dulson, C.; Roelfes, G., A designer enzyme for hydrazone and oxime
597 formation featuring an unnatural catalytic aniline residue. *Nat. Chem.* **2018**, *10* (9), 946-952.

598 46. Dirksen, A.; Hackeng, T. M.; Dawson, P. E., Nucleophilic Catalysis of Oxime Ligation. *Angew.*
599 *Chem. Int. Ed.* **2006**, *45* (45), 7581-7584.

600 47. Joshi, N. S.; Whitaker, L. R.; Francis, M. B., A Three-Component Mannich-Type Reaction for
601 Selective Tyrosine Bioconjugation. *J. Am. Chem. Soc.* **2004**, *126* (49), 15942-15943.

602 48. Joshi, N. S.; Whitaker, L. R.; Francis, M. B., A three-component Mannich-type reaction for
603 selective tyrosine bioconjugation. *Journal of the American Chemical Society* **2004**, *126* (49), 15942-
604 15943.

605 49. McFarland, J. M.; Joshi, N. S.; Francis, M. B., Characterization of a Three-Component Coupling
606 Reaction on Proteins by Isotopic Labeling and Nuclear Magnetic Resonance Spectroscopy. *J. Am.*
607 *Chem. Soc.* **2008**, *130* (24), 7639-7644.

608 50. Saimoto, H.; Yoshida, K.; Murakami, T.; Morimoto, M.; Sashiwa, H.; Shigemasa, Y., Effect of
609 Calcium Reagents on Aldol Reactions of Phenolic Enolates with Aldehydes in Alcohol. *J. Org. Chem.*
610 **1996**, *61* (20), 6768-6769.

611 51. Cohen, D. T.; Zhang, C.; Fadzen, C. M.; Mijalis, A. J.; Hie, L.; Johnson, K. D.; Shriver, Z.; Plante,
612 O.; Miller, S. J.; Buchwald, S. L. *et al.*, A chemoselective strategy for late-stage functionalization of
613 complex small molecules with polypeptides and proteins. *Nat. Chem.* **2019**, *11* (1), 78-85.

614 52. Szent-Györgyi, A.; Együd, L. G.; McLaughlin, J. A., Keto-Aldehydes and Cell Division. *Science*
615 **1967**, *155* (3762), 539.

616 53. Kalapos, M. P., Methylglyoxal in living organisms: Chemistry, biochemistry, toxicology and
617 biological implications. *Toxicol. Lett.* **1999**, *110* (3), 145-175.

618 54. Wang, Y.; Ho, C.-T., Flavour chemistry of methylglyoxal and glyoxal. *Chem. Soc. Rev.* **2012**, *41*
619 (11), 4140-4149.

620 55. Goldin, A.; Beckman Joshua, A.; Schmidt Ann, M.; Creager Mark, A., Advanced Glycation End
621 Products. *Circulation* **2006**, *114* (6), 597-605.

622 56. Rhee, S. Y.; Kim, Y. S., The Role of Advanced Glycation End Products in Diabetic Vascular
623 Complications. *Diabetes Metab. J.* **2018**, *42* (3), 188-195.

624 57. Chaudhuri, J.; Bains, Y.; Guha, S.; Kahn, A.; Hall, D.; Bose, N.; Gugliucci, A.; Kapahi, P., The Role
625 of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and
626 Causality. *Cell Metab.* **2018**, *28* (3), 337-352.

627 58. Lambert, J. D.; Sang, S.; Yang, C. S., Biotransformation of green tea polyphenols and the
628 biological activities of those metabolites. *Mol. Pharm.* **2007**, *4* (6), 819-25.

629 59. Li, X.; Zheng, T.; Sang, S.; Lv, L., Quercetin inhibits advanced glycation end product formation
630 by trapping methylglyoxal and glyoxal. *J. Agric. Food Chem.* **2014**, *62* (50), 12152-8.

631 60. Lv, L.; Shao, X.; Chen, H.; Ho, C. T.; Sang, S., Genistein inhibits advanced glycation end product
632 formation by trapping methylglyoxal. *Chem. Res. Toxicol.* **2011**, *24* (4), 579-86.

633 61. Lo, C.-Y.; Hsiao, W.-T.; Chen, X.-Y., Efficiency of Trapping Methylglyoxal by Phenols and
634 Phenolic Acids. *J. Food Sci.* **2011**, *76* (3), H90-H96.


635 62. Lo, C.-Y.; Li, S.; Tan, D.; Pan, M.-H.; Sang, S.; Ho, C.-T., Trapping reactions of reactive carbonyl
636 species with tea polyphenols in simulated physiological conditions. *Mol. Nutr. Food Res.* **2006**, *50* (12),
637 1118-1128.

- 638 63. Minakawa, M.; Guo, H.-M.; Tanaka, F., Imines that React with Phenols in Water over a Wide
639 pH Range. *The Journal of Organic Chemistry* **2008**, *73* (21), 8669-8672.
- 640 64. Casiraghi, G.; Salerno, G.; Sartori, G., A Novel One-Step Synthesis of 2-Hydroxyphenacyl
641 Alcohols. *Synthesis* **1975**, *1975* (03), 186-187.
- 642 65. Cordes, E. H.; Jencks, W. P., Nucleophilic Catalysis of Semicarbazone Formation by Anilines. *J.*
643 *Am. Chem. Soc.* **1962**, *84* (5), 826-831.
- 644 66. List, B.; Pojarliev, P.; Biller, W. T.; Martin, H. J., The Proline-Catalyzed Direct Asymmetric Three-
645 Component Mannich Reaction: Scope, Optimization, and Application to the Highly Enantioselective
646 Synthesis of 1,2-Amino Alcohols. *J. Am. Chem. Soc.* **2002**, *124* (5), 827-833.
- 647 67. Gilmore, J. M.; Scheck, R. A.; Esser-Kahn, A. P.; Joshi, N. S.; Francis, M. B., N-Terminal Protein
648 Modification through a Biomimetic Transamination Reaction. *Angew. Chem. Int. Ed.* **2006**, *45* (32),
649 5307-5311.
- 650 68. Chatalic, K. L. S.; Veldhoven-Zweistra, J.; Bolkestein, M.; Hoeben, S.; Koning, G. A.; Boerman,
651 O. C.; de Jong, M.; van Weerden, W. M., A novel ¹¹¹In-labeled anti-PSMA nanobody for targeted
652 SPECT/CT imaging of prostate cancer. *J. Nuc. Med.* **2015**.
- 653 69. Hatton, N. E.; Baumann, C. G.; Fascione, M. A., Developments in mannose-based treatments
654 for Uropathogenic Escherichia coli induced urinary tract infections. *ChemBioChem* **2021**, *22* (4), 613-
655 629.
- 656 70. Haupts, U.; Maiti, S.; Schwille, P.; Webb, W. W., Dynamics of fluorescence fluctuations in green
657 fluorescent protein observed by fluorescence correlation spectroscopy. *Proc. Nat. Acad. Sci.* **1998**, *95*
658 (23), 13573.
- 659 71. Peumans, W. J.; Damme, E. J. M. V., Plant Lectins: Versatile Proteins with Important
660 Perspectives in Biotechnology. *Biotechnol. Genet. Eng. Rev.* **1998**, *15* (1), 199-228.
- 661 72. Osman, M.; Mistry, A.; Keding, A.; Gabe, R.; Cook, E.; Forrester, S.; Wiggins, R.; Di Marco, S.;
662 Colloca, S.; Siani, L. *et al.*, A third generation vaccine for human visceral leishmaniasis and post kala
663 azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. *PLOS Neglected Tropical Diseases* **2017**,
664 *11* (5), e0005527.
- 665 73. Senko, M. W.; Hendrickson, C. L.; Paša-Tolić, L.; Marto, J. A.; White, F. M.; Guan, S.; Marshall,
666 A. G., Electrospray Ionization Fourier Transform Ion Cyclotron Resonance at 9.4 T. *Rapid*
667 *Communications in Mass Spectrometry* **1996**, *10* (14), 1824-1828.
- 668 74. McKean, P. G.; Delahay, R.; Pimenta, P. F. P.; Smith, D. F., Characterisation of a second protein
669 encoded by the differentially regulated LmcDNA16 gene family of Leishmania major. *Mol. Biochem.*
670 *Parasitol.* **1997**, *85* (2), 221-231.
- 671 75. Scafoglio, C.; Hirayama, B. A.; Kepe, V.; Liu, J.; Ghezzi, C.; Satyamurthy, N.; Moatamed, N. A.;
672 Huang, J.; Koepsell, H.; Barrio, J. R. *et al.*, Functional expression of sodium-glucose transporters in
673 cancer. *Proc. Nat. Acad. Sci. U.S.A.* **2015**, *112* (30), E4111.
- 674 76. Gillies, R. J.; Robey, I.; Gatenby, R. A., Causes and Consequences of Increased Glucose
675 Metabolism of Cancers. *J. Nuc. Med.* **2008**, *49* (Suppl 2), 24S.
- 676 77. Villani, L. A.; Smith, B. K.; Marcinko, K.; Ford, R. J.; Broadfield, L. A.; Green, A. E.; Houde, V. P.;
677 Muti, P.; Tsakiridis, T.; Steinberg, G. R., The diabetes medication Canagliflozin reduces cancer cell
678 proliferation by inhibiting mitochondrial complex-I supported respiration. *Mol. Metab.* **2016**, *5* (10),
679 1048-1056.
- 680 78. White, J. R., Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2
681 Inhibition. *Clin. Diabetes* **2010**, *28* (1), 5.
- 682 79. Crespy, V.; Aprikian, O.; Morand, C.; Besson, C.; Manach, C.; Demigné, C.; Rémésy, C.,
683 Bioavailability of Phloretin and Phloridzin in Rats. *J. Nutr.* **2001**, *131* (12), 3227-3230.
- 684 80. Rhile, I. J.; Markle, T. F.; Nagao, H.; DiPasquale, A. G.; Lam, O. P.; Lockwood, M. A.; Rotter, K.;
685 Mayer, J. M., Concerted Proton-Electron Transfer in the Oxidation of Hydrogen-Bonded Phenols. *J.*
686 *Am. Chem. Soc.* **2006**, *128* (18), 6075-6088.

- 687 81. Hammarström, L.; Styring, S., Proton-coupled electron transfer of tyrosines in Photosystem II
 688 and model systems for artificial photosynthesis: the role of a redox-active link between catalyst and
 689 photosensitizer. *Energy Environ. Sci.* **2011**, *4* (7), 2379-2388.
- 690 82. Huynh, M. T.; Mora, S. J.; Villalba, M.; Tejada-Ferrari, M. E.; Liddell, P. A.; Cherry, B. R.; Teillout,
 691 A.-L.; Machan, C. W.; Kubiak, C. P.; Gust, D. *et al.*, Concerted One-Electron Two-Proton Transfer
 692 Processes in Models Inspired by the Tyr-His Couple of Photosystem II. *ACS Cent. Sci.* **2017**, *3* (5), 372-
 693 380.
- 694 83. Costentin, C.; Robert, M.; Savéant, J.-M.; Tard, C., Inserting a Hydrogen-Bond Relay between
 695 Proton Exchanging Sites in Proton-Coupled Electron Transfers. *Angew. Chem. Int. Ed.* **2010**, *49* (22),
 696 3803-3806.
- 697 84. Niki, E., Action of ascorbic acid as a scavenger of active and stable oxygen radicals. *Am. J. Clin.*
 698 *Nutr.* **1991**, *54* (6 Suppl), 1119s-1124s.
- 699 85. Ducry, L.; Stump, B., Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal
 700 Antibodies. *Bioconjugate Chemistry* **2010**, *21* (1), 5-13.
- 701 86. Storz, P., Reactive oxygen species in tumor progression. *Front. Biosci.* **2005**, *10* (2), 1881-1896.

702
 703

SYNOPSIS TOC



704